On December 8, Imexpharm was honored to be included in the Top 10 Best Annual Reports of 2022 in the medium-cap group at the Listed Companies Awards (VLCA). This award is an expanded version of the Annual Report Awards, a program with a longstanding tradition of supporting Vietnam’s stock market and its community of listed companies.